You are in: eMedicine Specialties > Emergency Medicine > NEUROLOGY LabyrinthitisArticle Last Updated: Mar 27, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Barry Strasnick, MD, FACS, Chairman, Professor, Department of Otolaryngology - Head and Neck Surgery, Eastern Virginia Medical School Barry Strasnick is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Auditory Society, American College of Surgeons, American Medical Association, American Tinnitus Association, Ear Foundation Alumni Society, Norfolk Academy of Medicine, North American Skull Base Society, Society of University Otolaryngologists-Head and Neck Surgeons, Vestibular Disorders Association, and Virginia Society of Otolaryngology-Head and Neck Surgery Coauthor(s): Amalia Renee Steinberg, MD, Resident Physician, Department of Otolaryngology, Eastern Virginia Medical School; Mark E Boston, MD, Chairman, Department of Otolaryngology-Head and Neck Surgery, Wilford Hall Medical Center, Lackland Air Force Base Editors: Jerome FX Naradzay, MD, FACEP, Medical Director, Consulting Staff, Department of Emergency Medicine, Maria Parham Hospital; Medical Examiner, Vance County, North Carolina; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; J Stephen Huff, MD, Associate Professor of Emergency Medicine and Neurology, Department of Emergency Medicine, University of Virginia Health Sciences Center; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital Author and Editor Disclosure Synonyms and related keywords: viral labyrinthitis, serous labyrinthitis, bacterial labyrinthitis, suppurative labyrinthitis, sudden sensorineural hearing loss, neurolabyrinthitis, vestibulocochleitis, vestibulocochlearis, sudden hearing loss, ear infection, inner ear infection, ear labyrinth infection, hearing disorder, hearing disturbance, balance disorder, balance disturbance, vertigo, dysequilibrium, hearing loss, vestibular neuritis, herpes zoster oticus, Ramsay-Hunt syndrome, varicella-zoster virus, varicella reactivation, zoster reactivation, rubella, cytomegalovirus, CMV, mumps, measles, SNHL, herpes oticus, labyrinthine inflammation, labyrinthine disease, labyrinthine disorder, labyrinthine infection INTRODUCTIONBackgroundLabyrinthitis is an inflammatory disorder of the inner ear or labyrinth. Clinically, this condition produces disturbances of balance and hearing to varying degrees and may affect one or both ears. Bacteria or viruses can cause acute inflammation of the labyrinth in conjunction with either local infection or systemic infection. PathophysiologyThe anatomic relationships of the labyrinth, middle ear, mastoid, and subarachnoid space are essential to understanding the pathophysiology of labyrinthitis. The labyrinth is composed of an outer osseous framework surrounding a delicate membranous network that contains the peripheral sensory organs for balance and hearing. These sensory organs include the utricle, saccule, semicircular canals, and cochlea. Symptoms of labyrinthitis occur when infectious microorganisms or inflammatory mediators invade the membranous labyrinth and damage the vestibular and auditory end organs. The labyrinth lies within the petrous portion of the temporal bone adjacent to the mastoid cavity and connects with the middle ear at the oval and round windows. The labyrinth maintains connections with the central nervous system and subarachnoid space by way of the internal auditory canal and cochlear aqueduct. Bacteria may gain access to the membranous labyrinth by these pathways or through congenital or acquired defects of the bony labyrinth. Viruses typically spread to labyrinthine structures hematogenously or by way of the aforementioned preformed pathways. Viral and bacterial labyrinthitis are sufficiently different to warrant discussing them as separate disease processes. Viral labyrinthitis is characterized by a sudden unilateral loss of vestibular function and hearing. The acute onset of severe, often incapacitating, vertigo, frequently associated with nausea and vomiting, is characteristic of this disorder. The patient is often bedridden while the symptoms gradually subside. Vertigo eventually resolves after several days to weeks; however, unsteadiness and positional vertigo may persist for several months. Hearing loss is also present and may be the primary presenting symptom in many patients. Physical examination findings include spontaneous nystagmus toward the unaffected side with diminished or absent caloric responses in the affected ear. The hearing loss is usually mild to moderate and typically evident in the higher frequencies (>2000 Hz), although any degree or type of hearing loss may be present. An upper respiratory tract infection precedes the onset of symptoms in up to 50% of cases. Recurrent attacks are reported but are rare and may be confused with Ménière disease. Resolution of the vertigo and dysequilibrium is common and is due to partial recovery of vestibular function with concurrent central compensation of the remaining unilateral vestibular deficit. Return of hearing usually mirrors the return of vestibular function. Viral labyrinthitis is often confused with vestibular neuritis, and the terms are occasionally used interchangeably in the literature. However, most authors agree that vestibular neuritis is a disorder of the vestibular nerve and is not associated with hearing loss. Because the cochlea is affected in labyrinthine inflammation, hearing loss is always present in persons with viral labyrinthitis. Vestibular neuritis typically manifests as sudden acute vertigo without hearing loss in an otherwise healthy person. The condition is more common in the fourth and fifth decades of life and affects men and women equally. An upper respiratory tract infection often precedes the condition, and the disorder is more common in the spring and early summer. Histopathologic nerve studies of patients with vestibular neuritis demonstrate axonal loss, endoneurial fibrosis, and atrophy. These findings are consistent with a viral inflammatory etiology. The treatment of vestibular neuritis and viral labyrinthitis is similar. A unique form of viral labyrinthitis is herpes zoster oticus, or Ramsay-Hunt syndrome. The cause of this disorder is reactivation of a latent varicella-zoster virus infection occurring years after the primary infection. The initial symptoms are deep, burning, auricular pain followed a few days later by the eruption of a vesicular rash in the external auditory canal and concha. Vertigo, hearing loss, and facial weakness may follow in insolation or collectively. Symptoms typically improve over a few weeks; however, patients often suffer permanent hearing loss and persistent reduction of caloric responses. Viral infections can cause both congenital and acquired hearing loss. Rubella and cytomegalovirus are the best-recognized viral causes of prenatal hearing loss. Virally induced hearing loss in the postnatal period is usually due to mumps or measles. Viral infections are also implicated in idiopathic sudden sensorineural hearing loss (SNHL). These topics are covered in other articles (see Pediatrics, Measles; Pediatrics, Mumps; Cytomegalovirus Infection; Pediatrics, Rubella. Meningitis and otitis media may be complicated by bacterial labyrinthitis, which can occur by either direct bacterial invasion (suppurative labyrinthitis) or through the passage of bacterial toxins and other inflammatory mediators into the inner ear (serous labyrinthitis). Meningitis typically affects both ears, whereas otogenic infections typically cause unilateral symptoms. Bacteria spread from the cerebrospinal fluid to the membranous labyrinth by way of the internal auditory canal or cochlear aqueduct. Infections of the middle ear or mastoid most commonly spread to the labyrinth through a dehiscent horizontal semicircular canal. Usually, the dehiscence is the result of erosion by a cholesteatoma. Treatment of suppurative labyrinthitis is aimed at eradicating the underlying infection, providing supportive care to the patient, draining middle ear effusions or mastoid infections, and preventing the spread of infection. Labyrinthitis ossificans often follows suppurative labyrinthitis. In these cases, therefore, decisions regarding cochlear implantation must be made early. Meningitis also may result in progressive hearing loss secondary to necrosis and fibrosis of the membranous cochlea and labyrinth. Serous labyrinthitis occurs when bacterial toxins and host inflammatory mediators, such as cytokines, enzymes, and complement, cross the round window membrane, causing inflammation of the labyrinth in the absence of direct bacterial contamination. This condition is associated with acute or chronic middle ear disease and is believed to be one of the most common complications of otitis media. Toxins, enzymes, and other inflammatory products infiltrate the scala tympani, forming a fine precipitate just medial to the round window membrane. Penetration of the inflammatory agents into the endolymph at the basilar turn of the cochlea results in a mild high-frequency SNHL. Audiography testing reveals mixed hearing loss when a middle ear effusion is present. Vestibular symptoms may occur but are less common. Treatment is aimed at eliminating the underlying infection and clearing the middle ear space of effusion. The hearing loss is usually transient but may persist if the otitis is left untreated. FrequencyUnited StatesViral labyrinthitis is the most common form of labyrinthitis observed in clinical practice. One study reported that 37 of 240 patients who presented with positional vertigo had viral labyrinthitis. The prevalence of sudden SNHL is estimated at 1 case in 10,000 persons, with up to 40% of these patients complaining of vertigo or dysequilibrium.1 Auditory and vestibular symptoms develop in approximately 25% of patients with herpes oticus, in addition to the facial paralysis and vesicular rash that characterize the disease. Bacterial labyrinthitis is rare in the postantibiotic era, although bacterial meningitis remains a significant cause of hearing loss. Auditory symptoms, vestibular symptoms, or both may be present in as many as 20% of children with meningitis.2 Mortality/MorbidityDeaths associated with labyrinthitis are not reported except in cases of meningitis or overwhelming sepsis. The morbidity of labyrinthitis, especially bacterial labyrinthitis, is significant. In the pediatric population, the risk of hearing loss secondary to meningitis is estimated to be 10-20%.2, 3 Streptococcus pneumoniae appears to be the causative agent most likely associated with hearing loss, although some studies place Neisseria meningitidis as the most significant agent.2 Bacterial labyrinthitis, regardless of etiology, accounts for one third of all cases of acquired hearing loss. One study reported dizziness in 23% of patients following pneumococcal meningitis. Ménière disease may follow an episode of suppurative or serous labyrinthitis and is most likely due to fibrosis of the endolymphatic sac and altered Na+/K+ transport.1 AgeViral labyrinthitis is usually observed in adults aged 30-60 years and is rarely observed in children. Meningogenic suppurative labyrinthitis is usually observed in children younger than 2 years, which is the population most at risk for meningitis. Otogenic suppurative labyrinthitis can be observed in persons of any age in the presence of cholesteatoma and in untreated acute otitis media.4 Serous labyrinthitis is more common in the pediatric age group, in which the vast majority of both acute and chronic otitis media cases are observed. CLINICALHistoryA thorough medical history, including symptoms, past medical history, and medications, is essential to diagnosing labyrinthitis as the cause of the patient's vertigo or hearing loss.
PhysicalIn the physical examination include a complete head and neck examination with emphasis on the otologic, ocular, and cranial nerve portions of the examination. A brief neurologic examination is also necessary. Seek the presence of meningeal signs if meningitis is a consideration.
CausesLittle direct evidence suggests a viral cause for labyrinthitis; however, a wealth of epidemiologic evidence implicates a number of viruses as potentially causing inflammation of the labyrinth. Viral labyrinthitis is often preceded by an upper respiratory tract infection and occurs in epidemics. The histologic finding of axonal degeneration in the vestibular nerve suggests a viral etiology for vestibular neuritis.1 The bacteria that cause labyrinthitis are the same bacteria responsible for meningitis and otitis. Gram-negative organisms are found more commonly when cholesteatoma is the inciting factor.
DIFFERENTIALSBenign Paroxysmal Positional Vertigo CNS Causes of Vertigo Inner Ear, Autoimmune Disease Inner Ear, Ototoxicity Inner Ear, Perilymphatic Fistula Inner Ear, Sudden Hearing Loss Meniere Disease Migraine-Associated Vertigo Multiple Sclerosis Otitis Media Skull Base, Tumors, Other CPA Tumors Stroke, Ischemic Transient Ischemic Attack Vestibular Neuronitis
|
| Drug Name | Meclizine (Antivert) |
|---|---|
| Description | Decreases excitability of middle ear labyrinth and blocks conduction in middle ear vestibular-cerebellar pathways. Effects are associated with therapeutic effects in relief of nausea and vomiting. |
| Adult Dose | 25 mg PO q4-6h |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | May increase toxicity of CNS depressants, neuroleptics, and anticholinergics |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in angle-closure glaucoma, prostatic hypertrophy, pyloric or duodenal obstruction, and bladder neck obstruction |
| Drug Name | Dimenhydrinate (Dramamine) |
|---|---|
| Description | 1:1 salt of 8-chlorotheophylline and diphenhydramine thought to be useful, particularly, in treatment of vertigo. Through central anticholinergic activity, diminishes vestibular stimulation and depresses labyrinthine function. |
| Adult Dose | 50 mg PO/IM q4-6h or 100 mg supp q8h |
| Pediatric Dose | <2 years: Not established 2-6 years: Up to 12.5-25 mg PO q6-8h; not to exceed 75 mg/d 6-12 years: 25-50 mg PO q6-8h; not to exceed 150 mg/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; do not administer to neonates; IV products may contain benzyl alcohol, which has been associated with fatal "gasping syndrome" in premature infants and low-birth-weight infants |
| Interactions | Alcohol or other CNS depressants may have additive effect; caution when administering concurrently with potentially ototoxic antibiotics—may mask ototoxic symptoms, resulting in irreversible damage |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Do not treat severe emesis with antiemetic drugs alone; may contain either sulfites or tartrazine, which may cause allergic-type reactions in susceptible persons; may impede diagnosis of conditions such as brain tumors, intestinal obstruction, and appendicitis; may obscure signs of toxicity from overdosage of other drugs |
These agents are thought to work centrally by suppressing conduction in the vestibular cerebellar pathways.
| Drug Name | Scopolamine (Isopto) |
|---|---|
| Description | Blocks action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and CNS. Antagonizes histamine and serotonin action. Transdermal scopolamine may be most effective agent for motion sickness. Use in treatment of vestibular neuronitis limited by slow onset of action. |
| Adult Dose | 0.6 mg PO q4-6h or 0.5 mg transdermally q3d |
| Pediatric Dose | 6 mcg/kg/dose IV/IM/SC or 0.2 mg/m2 q6-8h; not to exceed 0.3 mg/dose |
| Contraindications | Documented hypersensitivity; primary glaucoma (including initial stages); pyloric obstruction; toxic megacolon; hepatic disease; paralytic ileus; severe ulcerative colitis; renal disease; obstructive uropathy; myasthenia gravis |
| Interactions | May decrease antipsychotic effectiveness of phenothiazines and/or phenothiazines may increase anticholinergic adverse effects (adjust phenothiazine dosages as necessary); tricyclic antidepressants may increase anticholinergic adverse effects (eg, dry mouth, constipation, urinary retention) because of additive effect (tricyclic antidepressants with less anticholinergic activity may be beneficial) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in elderly persons because of increased incidence of glaucoma; large doses may suppress intestinal motility and precipitate or aggravate toxic megacolon; may aggravate hiatal hernia associated with reflux esophagitis; may cause dysuria and necessitate catheterization in patients with prostatism; use cautiously in patients with asthma or allergies—reduction in bronchial secretions can lead to inspissation and formation of bronchial plugs |
By binding to specific receptor sites, these agents appear to potentiate effects of GABA and facilitate inhibitory GABA neurotransmission and other inhibitory transmitters. These effects may prevent vertigo and emesis.
| Drug Name | Diazepam (Valium) |
|---|---|
| Description | Effective in treating vertigo. Depresses all levels of CNS, including limbic and reticular formation, possibly by increasing activity of GABA, which is major inhibitory neurotransmitter. Individualize dosage and increase it cautiously to avoid adverse effects. |
| Adult Dose | 5-10 mg PO/IV/IM q4-6h |
| Pediatric Dose | <6 months: Not recommended >6 months: 0.05-0.3 mg/kg/dose IV/IM over 2-3 min, repeat in 2-4 h if necessary; or 0.12-0.8 mg/kg/d PO divided q6-8h; not to exceed 10 mg/dose |
| Contraindications | Documented hypersensitivity |
| Interactions | Phenothiazines, barbiturates, alcohols, and MAOIs increase CNS toxicity |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution with other CNS depressants, low albumin levels, or hepatic disease (may increase toxicity) |
These agents are effective in treating emesis, possibly because of their effects in the dopaminergic mesolimbic system.
| Drug Name | Promethazine (Phenergan) |
|---|---|
| Description | Antidopaminergic agent effective in treatment of emesis. Blocks postsynaptic mesolimbic dopaminergic receptors in brain and reduces stimuli to brainstem reticular system. |
| Adult Dose | 25 or 50 mg PO/IM/PR q4-6h |
| Pediatric Dose | <2 years: Contraindicated >2 years: 0.25-1 mg/kg PO/IV/IM/PR 4-6 times/d prn |
| Contraindications | Documented hypersensitivity; children <2 y (incidences of death due to respiratory depression) |
| Interactions | May have additive effects when used concurrently with other CNS depressants or anticonvulsants; with epinephrine may cause hypotension |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Can be associated with CNS depression, dry mouth, extrapyramidal symptoms, hypertension, and skin rash; caution in cardiovascular disease, impaired liver function, seizures, sleep apnea, and asthma |
| Drug Name | Prochlorperazine (Compazine) |
|---|---|
| Description | Antidopaminergic drug that blocks postsynaptic mesolimbic dopamine receptors, has anticholinergic effect, and can depress reticular activating system (possibly responsible for relieving nausea and vomiting). |
| Adult Dose | 5-10 mg PO/IM q6h 25-mg PR supp q12h |
| Pediatric Dose | 2.5 mg PO/PR q8h or 5 mg PO/PR q12h prn; not to exceed 15 mg/d 0.1-0.15 mg/kg/dose IM and change to PO as soon as possible IV administration not recommended |
| Contraindications | Documented hypersensitivity; bone marrow suppression; narrow-angle glaucoma; severe liver or cardiac disease |
| Interactions | Other CNS depressants or anticonvulsants may cause additive effects; with epinephrine, may cause hypotension |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Drug-induced Parkinson syndrome or pseudoparkinsonism occurs frequently; akathisia is most common extrapyramidal reaction in elderly persons; lowers seizure threshold; caution with history of seizures |
These agents may relieve vertigo, possibly through modulating the sympathetic system.
| Drug Name | Ephedrine (Pretz-D) |
|---|---|
| Description | Stimulates release of epinephrine stores, producing alpha- and beta-adrenergic receptors. |
| Adult Dose | 25 mg PO q4-6h |
| Pediatric Dose | <2 years: Not recommended 2-5 years: 3 mg PO q6-8h >5 years: 6.25 mg q6-8h |
| Contraindications | Documented hypersensitivity; angle-closure glaucoma; cardiac arrhythmias |
| Interactions | Theophylline, atropine, or MAOIs may increase toxicity; alpha- and beta-blockers decrease vasopressor effects; cardiac glycosides and general anesthetics increase cardiac stimulation |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adverse effects may include excitation, tremulousness, insomnia, nervousness, palpitation, tachycardia, other symptoms associated with sympathetic activation; bladder sphincter spasm, which may cause transient acute urinary retention, can also occur Caution in elderly persons and in patients who have diabetes mellitus, hyperthyroidism, hypertension, cardiovascular disease, prostatic hypertrophy, or cerebrovascular insufficiency |
The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Nicholas Y Lorenzo, MD, to the development and writing of this article.
Article Last Updated: Mar 27, 2008